Sun Pharma, Cassiopea sign territory expansion agreement for WINLEVI

26 Jul 2022 , 01:04 PM

Cassiopea is a subsidiary of Cosmo Pharmaceuticals N.V.. Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners. In 2021, Sun Pharma and Cassiopea had signed License and Supply Agreements for the United States and Canada markets. Sun Pharma launched WINLEVI in the US market in November 2021. Under the terms of the above referred agreements, Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia. Cosmo will be the exclusive supplier of the product. Cassiopea will receive an upfront payment of US$ 7 million, potential regulatory and sales milestones and customary double digit royalties on net sales. WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. The drug was approved by the U.S. Food and Drug Administration (FDA) in August 2020. Aalok Shanghvi, EVP & Head – Generic R&D, Generic Global BD and Emerging Markets, Sun Pharma said, ?WINLEVI is a new class of topical medication and it continues to generate significant interest amongst dermatologists in the US. The expansion of our agreement with Cosmo will enable us to make this new acne treatment available to patients in many more countries and is in line with our strategy to build a global portfolio of specialty products.? Sun Pharma is the worlds fourth largest specialty generic pharmaceutical company and Indias top pharmaceutical company. The company reported a consolidated net loss of Rs 2,277.25 crore in Q4 FY22 as against a net profit of Rs 894.15 crore in Q4 FY21. Consolidated sales from operations was at Rs 9,386.1 crore, a growth of 11% over Q4 last year. The scrip shed 0.55% to currently trade at Rs 863.25 on the BSE. Powered by Capital Market – Live News